LFCR Stock Forecast & Price Target

Lifecore Biomedical is a fully integrated CDMO that has shown strong execution in its commercial strategy, securing four site transfer wins since October 2025 and signing two new agreements with an existing customer. The company's urgent efforts to raise its profile as a manufacturing partner with potential customers are gaining traction, as evidenced by the positive cadence of recent wins. Additionally, Lifecore's Q4/25 stub period results beat expectations and demonstrated solid adjusted EBITDA growth and positive cash flow from operations. While the company's recently lowered guidance for FY/26 is a setback, the share price decline represents a compelling buying opportunity for investors, with the potential for significant outperformance over the next 3 to 5 years.

Lifecore Biomedical is facing significant revenue headwinds due to customer losses, inventory rebalancing, and delayed product launches, leading to uncertainty about future growth potential. This is evidenced by the company's modest revenue growth projection for 2027 and potential risks to achieving their predicted EBITDA and earnings estimates, which could negatively impact their stock valuation.